These data indicate that a TRC-resolution machinery is significantly overexpressed in MM, together with proliferative plasmablastic signatures and high-risk molecular abnormalities, including del17p, 1q gain, TP53 mutations, or double-hit genomic abnormalities (del17p/TP53 mutation).2 The gene discussed is TP53; the disease is Miyoshi myopathy.